No Data
No Data
Scotiabank Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Cuts Target Price to $1.4
Express News | Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Lowers Price Target to $1.5
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Flat for Week
Adaptimmune Therapeutics Is Maintained at Sector Outperform by Scotiabank
Adaptimmune Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), BioNTech SE (BNTX) and Alnylam Pharma (ALNY)